Results 111 to 120 of about 621,434 (269)

Phage Display Reveals VLRB-Mediated Recognition of Minimal Tumor Glycan Antigen Sialyl-Tn

open access: yesCurrent Issues in Molecular Biology
Sialyl-Tn (sTn) is a tumor-associated carbohydrate antigen (TACA) abundantly expressed by various types of carcinomas. While conventional antibody-based platforms have traditionally been used for the detection and targeting of sTn, alternative binding ...
Mark Rickard N. Angelia   +8 more
doaj   +1 more source

A previously uncharacterized O-glycopeptidase from Akkermansia muciniphila requires the Tn-antigen for cleavage of the peptide bond. [PDF]

open access: yesJ Biol Chem, 2022
Medley BJ   +9 more
europepmc   +1 more source

Anti‐hypercholesterolemic effects of barley and its role in the management of metabolic disorders: A comprehensive review

open access: yesJSFA reports, EarlyView.
Abstract The dietary and lifestyle practices have predominantly compromised human health, which are influenced by modernization and industrialization. Hypercholesterolemia, caused by the consumption of fatty and fried foods and a sedentary lifestyle, is a major modifiable risk factor for cardiovascular disease and commonly coexists with obesity ...
Muhammad Usman Khalid   +8 more
wiley   +1 more source

Analysis of Carbohydrates and Glycoconjugates by Matrix‐Assisted Laser Desorption/Ionization Mass Spectrometry: An Update for 2023–2024

open access: yesMass Spectrometry Reviews, EarlyView.
ABSTRACT The use of MALDI mass spectrometry for the analysis of carbohydrates and glycoconjugates is a well‐established technique and this comprehensive review is the twelfth update of the original article published in 1999 and brings coverage of the literature to the end of 2024.
David J. Harvey
wiley   +1 more source

Short synthetic glycopeptides successfully induce antibody responses to carcinoma-associated Tn antigen.

open access: yes, 2000
International audienceGlycopeptides containing a tumor-associated carbohydrate antigen (mono-, tri- or hexa-Tn antigen) as a B-cell epitope and a CD4+ T-cell epitope (PV: poliovirus or TT: tetanus toxin) were prepared for immunological studies.
Deriaud, E.   +6 more
core   +1 more source

Advancing Therapies for Mycobacterial Diseases: From Small Molecules to Host‐Directed Strategies

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT The global burden of multidrug‐resistant tuberculosis (MDR‐TB) and the rising incidence of nontuberculous mycobacterial (NTM) infections highlight the urgent need for innovative therapeutic strategies. Current treatments are prolonged, toxic, and increasingly compromised by resistance and limited diagnostic capacity.
Tânia Silva   +23 more
wiley   +1 more source

Association of Sialyl Tn antigen with cervical cancer lymph node status: An NRG oncology/GOG study. [PDF]

open access: yesGynecol Oncol, 2023
Benbrook DM   +12 more
europepmc   +1 more source

Diagnosis and Management of Prenatal Hereditary Pyropoikilocytosis

open access: yesPrenatal Diagnosis, EarlyView.
ABSTRACT Hereditary pyropoikilocytosis (HPP) is a severe hemolytic anemia caused by variants in SPTA1, SPTB, and EPB41. These weaken horizontal interactions in the erythrocyte cytoskeleton, causing membrane fragmentation and splenic sequestration. It will readily cause fetal anemia and often hydrops fetalis. Prenatal diagnosis requires first ruling out
Connor Hartzell   +6 more
wiley   +1 more source

A Multiple‐Model‐Informed Drug‐Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 572-582, March 2025.
ABSTRACT The antitumor efficacy of an intratumoral injection of a genetically engineered oncolytic vaccinia virus carrying human IL‐7 and murine IL‐12 genes (hIL‐7/mIL‐12‐VV) was demonstrated in CT26.WT‐bearing mice. In the CT26.WT‐bearing mouse model, the efficacy of the combination of hIL‐7/mIL‐12‐VV plus the anti‐programmed cell death protein (PD)‐1
Akihiro Yamada   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy